Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan...

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )

Melanoma outcomes improved by dual immunotherapy before surgery rather than...

Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands

Melanoma outcomes improved by dual immunotherapy before surgery rather than after ( Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands )

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Prof Don Dizon - Lifespan Cancer Institute, Providence, USA

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas ( Prof Don Dizon - Lifespan Cancer Institute, Providence, USA )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for...

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy

CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

More from ecancer